
A study unveiled crucial insights into cognitive impairments in neurodegenerative diseases, emphasizing the role of Lewy Body (LB) pathology. Based on extensive biomarker analysis, the study explores the impact on dementia and mild cognitive impairment (MCI) patients. Neurodegenerative diseases, like Lewy Body disease (LBD) and Alzheimer's disease (AD), present growing health challenges. Identifying biomarkers aids in timely diagnosis, disease understanding, and clinical trial candidate selection. Integrating LB status into AD and tau biomarker profiles, the analysis analyzed 883 participants, revealing the dual influence of AD and LB pathologies on cognitive decline.
Like
Save
Share